Argent BioPharma Limited (RGT.AX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 3 | 5 | 3 | 1 | 1 | - | 0 | - |
| Operating profit | AUD m | -15 | -12 | ||||||
| Net profit | AUD m | -16 | -17 | -21 | -18 | -18 | - | -10 | - |
| EPS reported | AUD | -0.31 | -0.14 | ||||||
| Operating cashflow per share | AUD | -0.16 | -0.12 | ||||||
| Capex per share | AUD | 0.00 | 0.00 | ||||||
| FCF per share | AUD | -0.16 | -0.12 | ||||||
| Free cash flow | AUD m | -9 | -9 | ||||||
| Net debt | AUD m | 7 | 7 | ||||||
| Book value equity | AUD m | -9 | -8 | ||||||
| Book value per share | AUD | -0.15 | -0.11 | ||||||
| Number of shares | m | 57.17 | 76.24 | ||||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -1.46 | -0.55 | ||||||
| P/S LTM | x | 21.57 | 10.68 | ||||||
| P/FCF LTM | x | -1.36 | -0.52 | ||||||
| EV/EBITDA LTM | x | -0.76 | -1.22 | ||||||
| EV/Sales LTM | x | 20.39 | 27.25 | ||||||
| Earnings Yield LTM | % | -3.85% | -3.48% | ||||||
| FCF Yield | % | -73.76% | -192.53% | ||||||
| Quality | |||||||||
| ROE | % | +206.77% | +118.54% | ||||||
| ROIC | % | +47.67% | -25.32% | ||||||
| Operating margin | % | -26.47% | -27.26% | ||||||
| Gross margin | % | +76.50% | -77.59% | ||||||
| FCF/Sales | % | -1590.87% | -2056.78% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -34.52% | -25.70% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.12 | -1.00 | ||||||
| Net Debt/EBITDA | x | -0.43 | -0.76 | ||||||
| EBIT/Net interest | x | -301.01 | -220.38 | ||||||
| Net debt/market cap | % | +1.71% | +2.00% | ||||||
| Net debt/Equity | x | -0.80 | -0.87 | ||||||
| Gross debt/equity | x | -0.96 | -1.06 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Argent BioPharma Limited, an Australian-headquartered biopharmaceutical firm founded in 2014, operates as a clinical-stage entity focused on developing innovative nano-engineered therapeutics. The company's core mission involves crafting treatments designed to re-establish a healthy balance between the nervous and immune systems, with its reach extending internationally to locations including Malta and Slovenia. Its diverse pipeline of product candidates is progressing through various clinical phases. CimetrA, a leading contender, is currently in Phase III trials targeting acute lung injury and Acute Respiratory Distress Syndrome (ARDS). For refractory epilepsy, CannEpil is undergoing Phase I clinical evaluation. Additionally, CogniCann is advancing through Phase IIA trials, aiming to offer symptomatic relief for Dementia and Alzheimer's disease. Beyond these clinical programs, Argent BioPharma is actively involved in the preclinical development of Irnican for Glioblastoma Multiforme and dedicates research and development efforts to wound treatment. The company has also forged a strategic partnership with SINTEF to enhance antimicrobial solutions for chronic wounds and explore potential applications in oncologic wound care. Previously known as MGC Pharmaceuticals Limited, the company officially rebranded to Argent BioPharma Limited.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Argent BioPharma Limited, an Australian-headquartered biopharmaceutical firm founded in 2014, operates as a clinical-stage entity focused on developing innovative nano-engineered therapeutics. The company's core mission involves crafting treatments designed to re-establish a healthy balance between the nervous and immune systems, with its reach extending internationally to locations including Malta and Slovenia. Its diverse pipeline of product candidates is progressing through various clinical phases. CimetrA, a leading contender, is currently in Phase III trials targeting acute lung injury and Acute Respiratory Distress Syndrome (ARDS). For refractory epilepsy, CannEpil is undergoing Phase I clinical evaluation. Additionally, CogniCann is advancing through Phase IIA trials, aiming to offer symptomatic relief for Dementia and Alzheimer's disease. Beyond these clinical programs, Argent BioPharma is actively involved in the preclinical development of Irnican for Glioblastoma Multiforme and dedicates research and development efforts to wound treatment. The company has also forged a strategic partnership with SINTEF to enhance antimicrobial solutions for chronic wounds and explore potential applications in oncologic wound care. Previously known as MGC Pharmaceuticals Limited, the company officially rebranded to Argent BioPharma Limited.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free